Authors: Sharon Salt, Editor
Tranexamic acid – a low-cost and widely available drug that prevents bleeding into the brain by inhibiting blood clot breakdown – could reduce deaths in individuals with traumatic brain injury by as much as 20%, depending on the severity of the injury.
The results, recently published in The Lancet, included more than 12,000 individuals who were recruited from 175 hospitals across 29 countries. Within the study, also termed the Clinical Randomization of an Antifibrinolytic in Significant Head Injury (CRASH-3), participants were given either intravenous tranexamic acid or a placebo.
The results indicated that within 3 hours post-injury with tranexamic acid administration, the number of deaths were reduced. This effect was greatest in participants who had mild and moderate traumatic brain injury (20% reduction in deaths). However, no clear benefit was observed in the most severely injured patients.